We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

79 hedge funds and large institutions have $593M invested in Acceleron Pharma in 2014 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

27% more funds holding

Funds holding: 62 → 79 (+17)

16% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 25

13% more capital invested

Capital invested by funds: $527M → $593M (+$66.8M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
79
Holders Change
+17
Holders Change %
+27.42%
% of All Funds
2.28%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
22
Increased
29
Reduced
25
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$61.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$36.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$36.1M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$13M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$11.4M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$11.7M
2
O
OrbiMed
New York
-$11.3M
3
BIT
BlackRock Institutional Trust
California
-$3.58M
4
VOYA Investment Management
VOYA Investment Management
Georgia
-$3.39M
5
DCM
Driehaus Capital Management
Illinois
-$3.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
26
Ascend Capital
California
$2.17M +$2.84M +63,000 New
TA
27
Teachers Advisors
New York
$1.99M +$2.28M +50,438 +695%
Jennison Associates
28
Jennison Associates
New York
$1.92M +$8.44K +187 +0.3%
BG
29
BlackRock Group
United Kingdom
$1.9M +$578K +12,807 +30%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$1.74M +$777K +17,212 +52%
Principal Financial Group
31
Principal Financial Group
Iowa
$1.37M -$27.1K -600 -1%
TCIM
32
TIAA CREF Investment Management
New York
$1.28M -$538K -11,929 -24%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.13M +$471K +10,428 +47%
TD Asset Management
34
TD Asset Management
Ontario, Canada
$1.08M +$907K +20,100 +181%
GPCM
35
Granite Point Capital Management
Massachusetts
$994K -$54.2K -1,200 -4%
BBA
36
Baker Bros. Advisors
New York
$992K -$55.7K -1,235 -4%
BOTOTLSJU
37
Board of Trustees of The Leland Stanford Junior University
California
$937K +$1.23M +27,154 New
CIP
38
Convergence Investment Partners
Florida
$809K +$1.06M +23,460 New
Two Sigma Investments
39
Two Sigma Investments
New York
$799K +$1.05M +23,164 New
Morgan Stanley
40
Morgan Stanley
New York
$793K -$751K -16,651 -42%
ARC
41
Absolute Return Capital
Massachusetts
$775K +$1.01M +22,462 New
FCMI
42
Foresite Capital Management I
California
$721K -$2.04M -45,108 -68%
BIM
43
BlackRock Investment Management
Delaware
$704K +$160K +3,537 +21%
SFM
44
Sphera Funds Management
Israel
$690K -$1.35M -30,000 -60%
SONJCPFA
45
State of New Jersey Common Pension Fund A
New Jersey
$621K -$1.13M -25,000 -58%
Charles Schwab
46
Charles Schwab
California
$592K +$143K +3,160 +23%
SIM
47
Spark Investment Management
New York
$569K +$745K +16,500 New
PP
48
PDT Partners
New York
$562K +$736K +16,299 New
TC
49
TFS Capital
Pennsylvania
$547K +$348K +7,703 +95%
TAM
50
Tocqueville Asset Management
New York
$494K +$218K +4,825 +51%
1
2
3 4

XLRN Hedge Fund Activity: Q1 2014 in Review

79 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2014, worth a combined $593M — up 13% from $527M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new XLRN positions and 5 closed out — a net gain of 17 holders — while 29 added to existing stakes and 25 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $61.3M. The largest seller was JP Morgan Chase, cutting an estimated $11.7M.

  • 79 institutional investors held Acceleron Pharma (XLRN) as of Q1 2014, up from 62 in Q4 2013.
  • Funds reported $593M of Acceleron Pharma stock for Q1 2014, up 13% quarter-over-quarter.
  • 22 funds opened new Acceleron Pharma positions in Q1 2014 and 5 closed out, a net change of +17 holders.
  • The largest Acceleron Pharma buyer in Q1 2014 was T. Rowe Price Associates, an estimated $61.3M added.
  • The largest Acceleron Pharma seller in Q1 2014 was JP Morgan Chase, an estimated $11.7M sold.

Based on aggregated 13F filings for Q1 2014.